Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hamilton

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
BMJ Open|January 29, 2020
Improving opioid guideline adherence: evaluation of a multifaceted, theory-informed pilot intervention for family physiciansPamela Leece, Yalnee Shantharam, Samah Hassam, et al.
Acta Oncologica (Stockholm, Sweden)|July 11, 2003
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancerMichael Hamilton, William Dahut, Otis Brawley, et al.
Iscience|June 18, 2021
Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulatorOnofrio Laselva, Zafar Qureshi, Zhi-Wei Zeng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumorsJean L Grem, Geraldine Morrison, Xiao-Du Guo, et al.
BMC Public Health|July 19, 2022
Supporting community overdose response planning in Ontario, Canada: Findings from a situational assessmentTriti Khorasheh, Caroline Bennett AbuAyyash, Maryam Mallakin, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2003
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorinJean L Grem, Mary G Quinn, Bruce Keith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patientsJean L Grem, Nancy Harold, Bruce Keith, et al.
Molecular Pharmacology|June 16, 2018
Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508delStephanie Chin, Maurita Hung, Amy Won, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Nature Communications|November 27, 2020
A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemiaKyle Spinler, Jeevisha Bajaj, Takahiro Ito, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
BMJ Open|January 29, 2020
Improving opioid guideline adherence: evaluation of a multifaceted, theory-informed pilot intervention for family physiciansPamela Leece, Yalnee Shantharam, Samah Hassam, et al.
Acta Oncologica (Stockholm, Sweden)|July 11, 2003
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancerMichael Hamilton, William Dahut, Otis Brawley, et al.
Iscience|June 18, 2021
Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulatorOnofrio Laselva, Zafar Qureshi, Zhi-Wei Zeng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2005
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumorsJean L Grem, Geraldine Morrison, Xiao-Du Guo, et al.
BMC Public Health|July 19, 2022
Supporting community overdose response planning in Ontario, Canada: Findings from a situational assessmentTriti Khorasheh, Caroline Bennett AbuAyyash, Maryam Mallakin, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2003
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorinJean L Grem, Mary G Quinn, Bruce Keith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patientsJean L Grem, Nancy Harold, Bruce Keith, et al.
Molecular Pharmacology|June 16, 2018
Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508delStephanie Chin, Maurita Hung, Amy Won, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Nature Communications|November 27, 2020
A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemiaKyle Spinler, Jeevisha Bajaj, Takahiro Ito, et al.
Pageof 7